Lumosa Therapeutics Co (ROCO:6535) Institutional Ownership: 3.45% (As of Aug. 11, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6535 Lumosa Therapeutics Co Ltd ROCO:6535
65 GF Score
Price NT$92.10
GF Value NT$128.03
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Lumosa Therapeutics Co Institutional Ownership?

Lumosa Therapeutics Co ROCO:6535 +1.43% 65 Institutional Ownership is 3.45% as of Aug. 11, 2026. GuruFocus rates ROCO:6535 with a GF Score™ of 65/100 and a GF Value™ of NT$128.03 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Lumosa Therapeutics Co's institutional ownership is 3.45%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Lumosa Therapeutics Co's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Lumosa Therapeutics Co's Float Percentage Of Total Shares Outstanding is 0.00%.

Lumosa Therapeutics Co Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Lumosa Therapeutics Co's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lumosa Therapeutics Co Institutional Ownership Chart

Lumosa Therapeutics Co Historical Data

The historical data trend for Lumosa Therapeutics Co can be seen below:

2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30 2026-07-31
Institutional Ownership 3.46 3.56 3.59 3.59 3.57 3.47 3.47 3.44 3.45 3.45
ROCO:6535
65GF Score
Lumosa Therapeutics Co Ltd ROCO:6535
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lumosa Therapeutics Co Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 3.45% mean?
Lumosa Therapeutics Co (ROCO:6535) has a Institutional Ownership of 3.45% as of Aug. 11, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Lumosa Therapeutics Co and its competitors.
Is Lumosa Therapeutics Co's Institutional Ownership too high?
Lumosa Therapeutics Co's current Institutional Ownership is 3.45%. Overall, Lumosa Therapeutics Co has a GF Score™ of 65/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lumosa Therapeutics Co's Institutional Ownership compare to VRTX and REGN?
Lumosa Therapeutics Co's Institutional Ownership of 3.45% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Lumosa Therapeutics Co and its competitors. Lumosa Therapeutics Co's current Institutional Ownership is 3.45%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lumosa Therapeutics Co stock overvalued right now?
Based on GuruFocus' analysis, Lumosa Therapeutics Co (ROCO:6535) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$128.03, compared to a current price of NT$92.10 — trading 28.1% below its estimated fair value. The current Institutional Ownership is 3.45%. Lumosa Therapeutics Co's overall GF Score™ is 65/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Lumosa Therapeutics Co (ROCO:6535), the current Institutional Ownership is 3.45% as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lumosa Therapeutics Co (ROCO:6535) Overvalued in 2026?

Based on GuruFocus' analysis, Lumosa Therapeutics Co stock appears to be undervalued. The current stock price of NT$92.10 is trading 28.1% below its estimated GF Value™ of NT$128.03. GuruFocus considers Lumosa Therapeutics Co to be Modestly Undervalued.

Key valuation signals for ROCO:6535:

  • Institutional Ownership: 3.45%
  • GF Value™: NT$128.03 vs. price of NT$92.10 (28.1% below fair value)
  • GF Score™: 65/100 with 3 warning signs

No single metric tells the full story. See the ROCO:6535 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lumosa Therapeutics Co Business Description

Address Park Street, 4th Floor, No. 3-2, Nangang District, Taipei, TWN, 11503
Lumosa Therapeutics Co Ltd develops new drugs. The company is engaged in the development of drugs for unmet medical needs in the fields of oncology and Neuroscience. Geographically, it derives a majority of its revenue from Taiwan and also has a presence in Asia, and America. The product pipeline of the company is Neuroscience, which includes LT 1001 for Postoperative Pain, LT 3001 for Acute Ischemic Stroke, LT 5001 for Uremic Pruritus, LT 6001 for Neurological disorder, and Oncology, including LT 2003 for Solid Tumor. It generates revenue from sales of goods.
65GF Score

Get the complete analysis for ROCO:6535

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$92.10
Price
NT$128.03
GF Value